Remedium Lifecare Limited today announced strong financial results for the quarter and half-year ended September 30, 2025, with profit after tax (PAT) nearly doubling to ₹862.34 lakh, up 85.5% from ₹464.88 lakh in Q1 FY26. EBITDA for the quarter rose 82.7% to ₹1,043.69 lakh, reflecting robust operational momentum. For the half-year, PAT surged to ₹1,327.22 lakh against ₹213 lakh in FY24-25, while consolidated revenue from operations reached ₹22,442.39 lakh. Earnings per share stood at ₹0.10 for the quarter and ₹0.15 for the half-year.
Commenting on the results, Whole-Time Director Adarsh Munjal highlighted the company’s operational discipline and portfolio strength, noting confidence in sustaining growth and profitability for the remainder of the financial year. The company also strengthened its governance with the appointment of Rambhajan Vishwakarma and Vignesh Laxman Gawde to the Board, underscoring a renewed focus on global expansion and CDMO service scaling.
In Kolkata, Remedium’s Q2 performance has caught investors’ attention, with brokers noting heightened trading activity and optimistic forecasts for specialty pharma growth in the city. Analysts expect the company’s expanding CDMO services and overseas operations to boost investor confidence in eastern India. With consolidated total assets at ₹1,62,318.10 lakh and global expansion plans underway, Remedium Lifecare appears well-positioned to capitalise on the growing demand for speciality pharma and chemical services.